.. Additional P-BNC tests are being developed for dedicated DNA Damage inhibitor cardiac diagnostic applications, including two multiplexed chips to assess cardiac risk for primary and secondary cardiac events, an expanded 5-plexed AMI diagnosis

panel, and an assay for biomarker of congestive heart failure (CHF) BNP (Figure 4). A P-BNC assay for NT-proBNP, Inhibitors,research,lifescience,medical another biomarker of CHF, is also in development. Further, as recent reports have shown, the combined measurement of CRP concentrations and leukocyte counts provides one of the most accurate methods available to date to assess an individual’s risk for heart disease. To this end, we have combined the bead-based and membrane-based P-BNC platforms to provide a dual-function CRP and white blood cell cardiac risk measurement tool, thus making the P-BNC the only POC system amenable for the combined measurement of both cellular and proteomic biomarkers of cardiac risk.29–31 Figure 4. (A) Specific molecules implicated in different stages of the cardiovascular disease cascade present themselves as putative

diagnostic biomarkers Inhibitors,research,lifescience,medical for CVD. Inhibitors,research,lifescience,medical (B) Dedicated P-BNC diagnostic applications for CVD include: (i) risk for primary cardiac event chip: … Our initial cross-sectional biomarker discovery study also demonstrated the potential utility for cTnI as a salivary biomarker of AMI despite its low concentration in this biological fluid. It must be noted that an essential Inhibitors,research,lifescience,medical prerequisite for the successful implementation of this biomarker in POC practice, whether in needle-prick-derived whole blood or saliva, depends on the availability of an ultra-sensitive method for its measurement. This is because the 99th percentile upper reference limit is the upper normal limit of the assay derived from a presumably normal healthy population. Levels below the 99th percentile upper reference limit are presumably normal, but this cutoff ultimately depends on the sensitivity and LOD of the assay. In the case of many current troponin assays, studies have shown that in actuality these 99th percentile reference limits include a heterogeneous patient population Inhibitors,research,lifescience,medical that

comprises “true” normal but also other patients with low levels who have elevated cardiac risk.32–35 These studies suggest that higher-sensitivity troponin assays are necessary; likewise, the advantage of ultrasensitive troponins is based on the premise that lower cutoff levels achieve higher sensitivity that will allow earlier found diagnosis, often within 90 minutes of presentation. Traditional POC cTnI measurements have resulted in limits of detection that are on the order of ~1 ng/ml. The most advanced laboratory-based instruments yield LOD values 50× or more lower than this. Indeed, there is a strong drive to increase sensitivity of this test, raising the bar for what is required as a prerequisite performance for a POC cTnI test. Sustained efforts have led to the development of an advanced P-BNC immunoassay for this gold standard of AMI diagnosis marker.